New Anti-Infectives Company, Allecra Therapeutics, Created With €15 Million Series A Financing

 New Anti-Infectives Company, Allecra Therapeutics, Created With €15 Million
                              Series A Financing

  PR Newswire

  LÖRRACH, Germany and SAINT LOUIS, France, April 18, 2013

LÖRRACH, Germany and SAINT LOUIS, France, April 18, 2013 /PRNewswire/ --

The creation of Allecra Therapeutics, a new company joining the established
European BioValley Life Sciences cluster, was announced today. Allecra is a
biopharmaceutical company dedicated to the development of novel antibiotics to
combat multi drug-resistant bacterial infections. Allecra's €15 million
Series A financing round was co-led by Edmond de Rothschild Investment
Partners and Forbion Capital Partners. EMBL Ventures also participated.
Allecra is a strategic partnership between the company's founders including
Nicholas Benedict, CEO of Allecra working in conjunction with Orchid Chemicals
& Pharmaceuticals Limited (Chennai, India).

Bacterial resistance to current antibiotics is widespread and growing
exponentially, compromising doctors' ability to treat serious infections in
patients receiving care both in hospitals and in the community. Governments,
non-governmental agencies and the medical community have called for increased
urgency and decisive action to combat what has been called the "epidemic of
antibiotic-resistance" ^[1] . Allecra's mission is to contribute to this
cause by developing new treatments which overcome emerging bacterial
resistance mechanisms, thereby saving lives of patients whose infections may
otherwise may be inadequately treated.

Nicholas Benedict, Allecra's CEO said, "To combat the increasing threat of
bacterial resistance the medical community is trying to conserve the use of
currently available antibiotics. At the same time, the biopharmaceutical
industry is working to find new antibiotics. These objectives are
complimentary activities in the increasingly urgent battle against bacterial
resistance. Allecra has been formed in order to find new cures for some of
the most widespread and hardest to treat resistant infections."

Commenting on this partnership, Orchid's Chairman & Managing Director, Mr K.
Raghavendra Rao said, "We have always believed in building collaborative
business models to achieving our vision. This strategic partnership with
Allecra is yet another demonstration of how we can create value by harnessing
the relative strengths of each company."

Holger Reithinger of Forbion Capital Partners and member of Allecra's Board
said, "It is our shared objective at Allecra to deliver to the medical
community novel treatments to help fight the epidemic of bacterial resistance.
We have a specialist team, each of whom is deeply experienced in the
development of antibiotics and which collectively is supported by a
world-leading group of Opinion Leaders."

--------------------------------------------------

1. Infectious Disease Society of America, Spelberg B., et al. The Epidemic of
Anti-Biotic Resistant Infections CID 2008:46

Olivier Litzka of Edmond de Rothschild Investment Partners and member of
Allecra's Board added, "Allecra's strategic partnership with Orchid is an
innovative collaboration bringing together Allecra's strong development
capability with Orchid's track record in antibiotic research and
manufacturing. Allecra is supported by a Scientific Advisory Board consisting
of world-renowned experts and Allecra's Board of Directors comprises key
appointments of entrepreneurs and industrialists with records of success in
this area.  This is a new company built on a solid foundation for success."

About Allecra Therapeutics

Allecra is a biopharmaceutical company established in 2013 in the European
BioValley Life Sciences cluster which is located in the Upper Rhein valley
encompassing northwest Switzerland, southeastern Germany and the Alsace Region
of France. Allecra is focussed on the development of novel treatments to
combat multi drug-resistant bacterial infections. The company is based on a
strategic partnership between its Founders, Orchid Chemicals and
Pharmaceuticals Ltd. (Chennai, India) and its lead investors Forbion Capital
Partners and Edmond de Rothschild Investment Partners. Allecra's mission is
to contribute towards the global effort to combat antibiotic resistance by
developing new treatments which overcome emerging resistance mechanisms
thereby saving lives of patients whose infections may otherwise may be
inadequately treated. For more information on Allecra please visit
http://www.allecra.com or email info@allecra.com .

About Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) was established in Chennai,
India in 1992 as an export-oriented unit (EOU). Orchid is a vertically
integrated company spanning the entire pharmaceutical value chain from
discovery to delivery with established credentials in research, manufacturing
and marketing. Orchid today ranks among the top 15 pharmaceutical companies in
India and enjoys a multi-therapeutic presence across segments like
anti-infectives, anti-inflammatory, central nervous system (CNS), cardio
vascular segment (CVS), nutraceuticals and other oral and sterile products.
Orchid's pharmaceutical solutions include active pharmaceutical ingredients
(API), finished dosage forms, new drug discovery (NDD), novel drug delivery
systems (NDDS) and contract research and manufacturing services (CRAMS).
Orchid is globally present across 70+ countries through alliances, joint
ventures and partnerships with globally reputed majors.

About Forbion Capital Partners

Forbion Capital Partners is a dedicated Life Sciences venture capital firm
with offices in Naarden, The Netherlands, and Munich, Germany. Forbion invests
in life sciences companies in drug discovery & development as well as medical
device companies addressing substantial unmet medical needs. Forbion's
investment team of nine investment professionals has built  an
impressive performance track record since the late nineties with successful
investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella,
Alantos, Acorda, Fovea, PanGenetics, Argenta Discovery and most recently
Biovex and Pathway Medical. Current assets under management exceed $550M,
split between four active funds and comprising some 29 promising portfolio
companies. Forbion Capital Partners Fund II is supported by the European
Investment Fund through its ERP and LfA facilities. Forbion co-manages
Biogeneration Ventures, an early stage fund focused on (academic) spin-outs
and seed investments in the Netherlands. For more information, please visit
http://www.forbion.com .

About Edmond de Rothschild Group

Edmond de Rothschild Investment Partners is the private equity affiliate of
the Edmond de Rothschild Group which is specialised in asset management and
private banking (EUR 125bn under management, 2,900 employees and 30 offices
throughout the world). Founded in 1953, the Group has been chaired since 1997
by the founder's son, Baron Benjamin de Rothschild .

About EMBL Ventures

EMBL Ventures is an independent venture capital investor that manages two
Funds with a total of €68 million capital on behalf of major European
institutional and private investors. Currently it invests with its second
Fund, the EMBL Technology Fund II. EMBL Ventures' close relationship with the
European Molecular Biology Laboratory (EMBL) and its technology transfer
organization EMBL Enterprise Management Technology Transfer GmbH (EMBLEM)
allows it to finance disruptive technologies in an entrepreneurial start-up
environment, aiming ultimately for a transaction with a partner that is
seeking to acquire external product innovation. EMBL Ventures is exclusively
focused on life-science investments. EMBL Technology Fund II is supported by
the European Communities Growth and Employment Initiative, MAP - ETF Start up
Facility.

For further information please contact

Allecra Therapeutics GmbHNicholas Benedict +41-79-592-2005 info@allecra.com